Since becoming a leader of Keyhole Limpet Hemocyanin (KLH)
production, Stellar Biotechnologies Inc. (OTCQB: SBOTF) continues its
objectives towards commercial expansion of its product with immunotherapy
treatments. KLH is an immune stimulating protein that aids in fighting immune
deficient illnesses like cancer, Alzheimer’s Disease, and many inflammatory
diseases. The company has successfully maintained its partnerships with various
companies to meet its goals.
Since 2013, Stellar and Amaran Biotechnologies Inc. have
collaborated on manufacturing the OBI-822 immunotherapy that uses KLH as an
important immune stimulator. The companies have completed all of their initial
objectives and will now focus on commercial manufacturing to the wider market.
Similarly, in April 2015, Stellar expanded its agreement with Neovacs S.A. to
continue supplying the company with Stellar KLH in their IFNα-Kinoid
immunotherapy treatment of Lupus.
To keep up with emerging immunotherapy innovations, Stellar
collaborated with Ostiones Guerrero SA de CV in July to obtain a site in Baja
California, Mexico to develop another aquaculture production location. The
company expects to use this location in hopes of accelerating KLH production to
meet the needs of the growing market.
With the goal of expansion, Stellar recently consolidated
the company’s common shares (outstanding and issued) on the grounds of one (1)
post-consolidated share for every ten (10) pre-consolidated shares in a reverse
stock split maneuver so that these shares can be traded on the NASDAQ market.
With NASDAQ’s approval, this could help Stellar spread its brand to more
investors while increasing assets to shareholders.
Stellar still commits to new technology related to KLH and
how to use its different forms effectively in various treatments. To solidify
its unswerving goals, the company presented a poster at the Annual Meeting of
the American Association of Immunologists called, “Measuring the Properties of
Different Forms of Keyhole Limpet Hemocyanin (KLH) Reveals Important
Differences.” This highlights the different ways KLH can prompt immune
responses in various therapies.
The company also stands behind the United Nations’ September
declaration of protecting and using oceans for sustainable development. This
declaration aligns with Stellar’s mission of using aquaculture science to
manufacture more KLH for therapies.
In May, the company expanded its online communication to
Facebook, Twitter, and Google+/YouTube to convey educational content and
updates. By spreading its brand, Stellar aims to collaborate with more
immunotherapy manufacturers to bring successful treatments to patients while
also creating valuable stock to investors.
For more information on Stellar Biotechnolgies Inc., please
visit http://www.stellarbiotechnologies.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
